Fig. 1.

The effect of therapy on the airway response to inhaled allergen; demonstrating time course of the mean (SD) decline in FEV₁ (expressed as percent of pre-challenge FEV₁ values) following allergen challenge to assess the efficacy of ten days of treatment with an inhaled corticosteroid (budesonide; 400 mcg daily) and a leukotriene antagonist (montelukast; 10 mg daily) on the early and late airway response to inhaled allergen in ten asthmatic subjects. Significant attenuation of the early response was observed with either montelukast or the combination of budesonide and montelukast when compared with placebo. Significant attenuation of the late airway response was observed by all three active treatment regimens when compared with placebo.⁴⁹